Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation

Hepatobiliary and Pancreatic Diseases International

Volumn 7, Issue 4, 2008, Pages 357-361

  Lu, An Wei ^a   Zheng, Shu Sen ^a   Wu, Mei Ping ^a   Shen, Yi ^b   Yang, Rong Wei ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

HBV DNA; HBV recurrence; Lamivudine; Liver transplantation

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VIRUS DNA;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; PREOPERATIVE TREATMENT; RECURRENCE RISK; RECURRENT INFECTION; RETROSPECTIVE STUDY; VIRUS DETECTION;

DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LAMIVUDINE; LIVER TRANSPLANTATION; MUTATION; MYCOPHENOLIC ACID; ODDS RATIO; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 49749088710     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gish RG, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl 2006;12:S54-64.
2. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-85.
3. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007;132:1574-1585.
4. Schreibman IR, Schiff ER. Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006;5:8.
5. Wu J, Zheng SS. Liver transplantation in China: problems and their solutions. Hepatobiliary Pancreat Dis Int 2004;3: 170-174.
6. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003;39:S111-115.
7. Zuckerman JN. Review: hepatitis B immune globulin for prevention of hepatitis B infection. J Med Virol 2007;79: 919-921.
8. Oldakowska-Jedynak U, Paczek L, Foroncewicz B, Mucha K, Nyckowski P, Zieniewicz K, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin. Ann Transplant 2007;12: 28-32.
9. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008;6:696-700.
10. Polak WG, Gladysz A, Rotter K. Prevention of hepatitis B recurrence after liver transplantation. Ann Transplant 2005;10:11-16.
11. Jiao ZY, Yan LN, Li B, Zeng Y, Wen TF, Lu SC, et al. Liver transplantation for chronic hepatitis B patients with lamivudine monotherapy or lamivudine combined with individualized low-dose hepatitis B immunoglobulin treatment. Zhonghua Gan Zang Bing Za Zhi 2007;15:804-808.
12. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008;14:935-945.
13. Wu LM, Xu X, Zheng SS. Hepatitis B virus reinfection after liver transplantation: related risk factors and perspective. Hepatobiliary Pancreat Dis Int 2005;4:502-508.
14. Yilmaz N, Shiffman ML, Todd Stravitz R, Sterling RK, Luketic VA, Sanyal AJ, et al. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2008;28: 72-78.
15. Seehofer D, Rayes N, Naumann U, Neuhaus R, Müller AR, Tullius SG, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001;72: 1381-1385.
16. Ben-Ari Z, Mor E, Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J Intern Med 2003;253:544-552.
17. Mohanty SR, Cotler SJ. Management of hepatitis B in liver transplant patients. J Clin Gastroenterol 2005;39:58-63.
18. Seehofer D, Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation 2005;80:S120-124.
19. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895-902.
20. Seehofer D, Rayes N, Steinmüller T, Müller AR, Jonas S, Settmacher U, et al. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol 2002;40:795-799.
21. Lee HW, Suh KS, Yi NJ, Yang SH, Cho EH, Cho JY, et al. Preoperative lamivudine therapy in HBV DNA positive recipients: is it always necessary? Hepatogastroenterology 2007;54:1783-1787.